| Metric | Q1'25 | Q2'25 | Change |
|---|---|---|---|
| Total Revenue | $650M (+18.5% YoY) | $676M (+16.1% YoY) | -240 bps deceleration |
| Commercial Subscription Revenue | $282M | $299M | Raised FY25 guide on strength |
| R&D Subscription Revenue | $367M | $377M | Guide whipsaw: cut Q1, raised Q2 |
| Non-GAAP Operating Income | $261M (40.2%) | $280M (41.4%) | +120 bps margin expansion |
| Services Revenue | Low single-digit growth | Still pressured by timing delays | Customer direct contracting emergence |
| Vault CRM Wins | Strong quarter (Vault) | 14 wins, exclusively Vault CRM | Accelerating cadence vs pre-migration |
| Top 20 Pharma Activity | 3 wins spanning multiple products | Multiple wins across safety, quality, R&D | Maintained momentum despite macro |
| Crossix Business | Called out strength | Very strong quarter, audience business focus | Consecutive strong performance |
| Gross Margin | Not specifically called out | Improved via mix shift and efficiency | Non-CRM products + services efficiency |
| Headcount Growth | Focused hiring mentioned | +1% YoY | Efficiency gains while maintaining investment |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.